Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Arsenic Trioxide for p53-Mutated AML/MDS
NCT03855371Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jan 2018
- Primary completion
- Jul 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of arsenic trioxide in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoint: Side effect. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03855371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03855371.